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Abstract Differences in hormone receptor and HER-2
status between primary tumour and corresponding relapse
could have a substantial impact on clinical management of
patients. The aim of this study was to evaluate change in
expression of hormone receptors and HER-2 status between
primary tumour and corresponding local recurrence or
distant metastasis. We analysed 140 primary tumours and
related recurrent or metastatic samples. Hormone receptors
status was evaluated by immunohistochemistry, while HER-
2 status by immunohistochemistry and silver in situ
hybridisation. A change in HER-2 was rare; 3.7% of cases
by immunohistochemistry and only 0.7% by silver in situ
hybridisation analysis. A change in estrogen and proges-
terone receptors was seen in 6.4% and 21.4% of cases,
respectively. Estrogen receptor change was not affected by
adjuvant therapy, whereas progesterone receptor was
influenced by adjuvant chemotherapy associated to hor-
mone therapy (P=0.0005). A change in progesterone
receptor was more frequent in distant metastases than in
local recurrences (P=0.03). In the setting of estrogen
receptor positive tumours, patients with progesterone
receptor loss in local recurrence had a statistically signif-
icant lower median metastasis free survival compared to
others patients; progesterone receptor positive, 112 months;
progesterone receptor negative, 24 months (P=0.005). A
change between primary tumour and corresponding relapse
is frequent for progesterone receptor, infrequent for estro-
gen receptor and rare for HER-2. In cases with changes in
HER-2, it is worthwhile reassessing HER-2 status with both
immunohistochemistry and in situ hybridisation analysis.
Progesterone receptor loss seems to be influenced by
therapy and to correlate with a worse prognosis.
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Introduction
Hormone receptor and HER-2 status are the most important
predictive markers in breast cancer. Their assessment is
generally performed on resected primary tumour (PT) in
order to select patients eligible for hormone and HER-2
directed therapies [1–7]. Most of the tumours that do
respond initially to targeted therapies will gain acquired
resistance [8]. Differences in hormone receptor and HER-2
status between PT and corresponding relapse could help to
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DOI 10.1007/s00428-011-1097-7explain this acquired resistance and have a substantial
impact on clinical management of these patients. Neverthe-
less, the results reported in different studies, concerning
expression of biomarkers in PT and corresponding metas-
tasis, are not homogeneous (Table 1)[ 1–30]. There are
many hypotheses that could explain biomarkers change
between PT and corresponding metastasis: clonal selection
for hormone receptor and HER-2 during tumour progres-
sion due to intratumoral heterogeneity and/or to selective
pressure from therapy; independent evolution of an early
stem cell clone in both sites, instead of a linear progression
from the PT to metastasis; false shifts related to detection
and evaluation including tissue processing, reagent vari-
ability, type of test and scoring interpretation [1, 2, 8, 14,
18, 22, 26, 31]. The aim of this study was to compare the
expression of estrogen receptor (ER), progesterone receptor
(PR) and HER-2 status between PTand corresponding local
recurrence (LR) or distant metastasis (DM) to evaluate
whether therapy can modify this status and whether
biomarkers change can affect prognosis.
Materials and methods
For this study, we considered all consecutive breast cancer
DM and LR diagnosed at the Institute of Pathology of
Sacro Cuore Hospital, Negrar, V erona between January
1998 and December 2009. There were 198 patients with
histological samples of breast LR or DM. For 140 of these
patients, the corresponding PTsamples were retrieved from
the files of the Institute of Pathology. For the remaining 58
cases, corresponding PTsamples were not available. Cases
Table 1 Literature review of ER, PR and HER-2 discordance between primary tumours and corresponding metastatic sites
Cases Metastatic sites Type of analysis ER (%) PR (%) HER-2 (%)
Andersen 1988 [10] 143 ALM/DM Biomarkers reassessment 10
Li 1994 [17] 83 LR/DM Biomarkers reassessment 29 44
V an Agthoven 1995 [28] 26 ALM Biomarkers reassessment 0
Johnston 1995 [8] 34 LR Biomarkers reassessment 23 26
Kuukasjarvi 1996 [16] 50 LR Biomarkers reassessment 24 24
Shimizu 2000 [24] 21 LR/DM Biomarkers reassessment 25 30 0
Zheng 2001 [30] 52 ALM Biomarkers reassessment 6
Tanner 2001 [6] 45 LR/DM Biomarkers reassessment 0
Simon 2001 [25] 125 ALM Biomarkers reassessment 3
Gancberg 2002 [1] 100 DM Biomarkers reassessment 6
Vincent-Salomon 2002 [29] 44 DM Biomarkers reassessment 4
Edgerton 2003 [13] 113 LR/DM Biomarkers reassessment 20
Iguchi 2003 [15] 87 ALM Biomarkers reassessment 24
Carlsson 2004 [12] 47 ALM Biomarkers reassessment 0
Regitnig 2004 [21] 31 DM Biomarkers reassessment 10
Gong 2005 [2] 60 ALM/LR/DM Biomarkers reassessment 3
Zidan 2005 [7] 58 LR/DM Biomarkers reassessment 14
Lower 2005 [20] 200 LR/DM Reports review 30 39
Tapia 2007 [26] 105 DM Biomarkers reassessment 3
Guarneri 2008 [3] 75 LR/DM Reports review 22 36 16
Gomez-Fernandez 2008 [14] 278 LR/DM Biomarkers reassessment 3
Santinelli 2008 [22] 119 ALM/LR/DM Biomarkers reassessment 14
Broom 2009 [11] 100 DM Reports review 18 37 5
Simmons 2009 [5] 29 DM Biomarkers reassessment 12 28 8
Liedtke 2009 [18] 211 LR/DM Reports review 18 40 14
Idirisinghe 2010 [4] 117 LR/DM Biomarkers reassessment 16 38 5
Sari 2010 [23] 78 LR/DM Biomarkers reassessment 36 54 15
Thompson 2010 [27] 137 LR/DM Biomarkers reassessment 10 25 3
Amir 2010 [9] 271 LR/DM Biomarkers reassessment 13 34 5
Locatelli 2010 [19] 255 DM (liver) Reports review 14 48 14
ALM axillary lymph node metastases, LR local recurrences, DM distant metastases, ER estrogen receptor, PR progesterone receptor
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In cases with multiple LR or DM, we considered samples
obtained from the first (chronologically) detected LR or
DM site. For each PT, the following information was
obtained from pathology reports: patient age, histological
type, tumour size, grading, ER, PR and HER-2 status.
Data regarding adjuvant therapy and follow-up were
retrieved from the files of the department of oncology.
Tissue samples were fixed in 10% buffered formalin for
20–24 h before processing and embedding. Hormone
receptors status was evaluated by immunohistochemistry
(IHC), while HER-2 status by IHC and silver in situ
hybridisation (SISH). All samples were reassessed with the
same validated staining techniques to reduce inter-
laboratory variability and reviewed by a single dedicate
breast pathologist (G.B.) to decrease inter-observer vari-
ability. These results were compared to the original report;
this comparison was possible in 280 samples for ER and
PR and in 82 samples for HER-2 because, in our institute, it
has been evaluated routinely since 2005.
A high loss rate of PR in LR and DM has been
previously reported (Table 1). On this way, we examined
whether this finding could have any clinical impact,
evaluating metastasis free survival (MFS), defined as
elapsed months since LR to first DM, in the subset of
patients with ER positive PTand LR, but with different PR
status. ER negative tumours were excluded because there
were no ER negative/PR positive tumours, and then the
choice of therapy was not influenced by PR status. Patients
with DM prior or synchronous to LR were excluded,
because patient’s management was determined by the
presence of DM, regardless of LR features.
Immunohistochemistry
IHC to detect hormone receptors was performed with the
CONFIRM® anti-ER clone SP1, rabbit monoclonal primary
antibody and CONFIRM® anti-PR clone 1E2 (VMS,
Tucson AZ, USA) using an automated BenchMark XT
staining system (VMS, Tucson AZ, USA) with a reduced
CC1 (pH 8.2 for 30 min) unmasking protocol. Sections
were incubated at 37°C for 20 min and then developed with
the UltraView Universal Dab Detection Kit. According to
the ASCO/CAP guidelines, we defined as positive tumours
with ER/PR ≥1% [32]; we considered as shifted those
cases that changed from ≥1% to <1% and vice versa.
HER-2 was performed using the primary antibody
PA THW AY® anti-HER2/neu clone 4B5 (VMS, Tucson AZ,
USA) in the automated BenchMark XT staining system
(VMS, Tucson, AZ, USA) using a reduced (pH 8.2 for
30 min) CC1-unmasking protocol. Sections were incubated
at 37°C for 16 min and developed with the UltraView
Universal Dab Detection Kit.
According to ASCO/CAP guidelines, HER-2 expression
was scored as 0 (no staining or weak/moderate, incomplete/
complete staining in ≤10% of cells), 1+ (weak and
incomplete staining in >10% of cells), 2+ (weak/moderate
complete staining in >10% of cells or strong, complete
staining in ≤30% of cells) and 3+ (strong, complete
staining in >30% of cells) [33].
In addition, we detected Ki-67 (CONFIRM® anti-Ki-67
clone 30–9, rabbit monoclonal primary antibody) and E-
cadherin (clone 36, mouse monoclonal primary antibody) in
all cases using an automated BenchMark XT staining
system (VMS, Tucson, AZ, USA) with a reduced CC1
(pH 8.2 for 30 min) unmasking protocol. Sections were
incubated at 37°C for 20 min and then developed with the
UltraView Universal Dab Detection Kit.
Silver in situ hybridisation
SISH was performed in BenchMarK XT staining system
(VMS, Tucson AZ, USA) according to the manufacturer’s
instructions. Testing for the HER-2 gene and chromosome
17 was performed on sequential sections. Briefly, formalin-
fixed, paraffin-embedded tissues were cut in 4.5 μm thick
sections, put on polarized slides, dried overnight at 40°C
and placed in the automated staining system (one slide for
each probe). The principal steps were heat pre-treatment
with citrate buffer pH 6 at 90°C, enzymatic digestion with
protease at 37°C for 8 min, probe dispensation, denatur-
ation at 95°C for 8 min, hybridisation at 52/54°C for 3 h,
stringent washes, indirect detection and counterstaining
with haematoxylin. Slides were progressively dehydrated
with increasing alcohol concentrations, cleared in xylene
and mounted. HER-2 3-in-1 xenograft control slides were
used as reaction and quality controls. The number of signal
deposits was counted in 20 tumour nuclei in two distinct
areas, in the slide reactive for HER-2 and in the same areas
in the slide reactive for chromosome 17. The HER-2/
chromosome 17 ratio was calculated and scored according
to ASCO/CAP guidelines: ratio <1.8, HER-2 gene not
amplified; ratio >2.2, HER-2 gene amplified; ratio between
1.8 and 2.2, uncertain [33].
Discordant HER-2 status was considered when there was
a shift from 0, 1+, 2+ (SISH non-amplified) IHC to 2+
(SISH amplified) or 3+ IHC and vice versa. In case of
discordance between IHC and SISH, the HER-2 was
defined according to the SISH status. In our routine work
up for breast cancer, the discordance rate between IHC and
SISH to HER-2 determination is 2.8%.
Statistical analysis
Agreement for ER, PR and HER-2 between PT and
corresponding relapses wase x p r e s s e db yd i s c o r d a n c e
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or negative) of ER, PR and HER-2 between PT and
corresponding metastases were calculated using the
McNemar’s test. Comparisons of percentages between
groups were performed using the chi-square or Fisher’s
exact test. The MFS in the group of patients considered
was described by the Kaplan–Meier method and com-
pared with the use of the log-rank test. A two-sided P
value of 0.05 was considered a statistically significant
difference.
A multivariable Cox proportional hazard regression
model was used to evaluate the independent prognostic
relevance of the following factors for MFS: PT patho-
logical size (T1 vs T2–T4); pathological node status
(negative vs positive ≤3 vs positive >3); PT histological
g r a d e( g r a d e1 –2 vs grade 3), PT Ki-i67 level (examined
as continuous variable); PT/LR HER-2 status (negative
vs positive); PT/LR ER positive proportion (examined as
continuous variable); LR free survival (≤1y e a rv s1 –
5 years vs >5 years); PR status (PR positive in PT and LR
vs PR positive PT and negative LR vs PR negative in PT
and LR). Stata/IC for Windows version 11.1 was used for
all analyses.
Results
Pathological results
We analysed 140 PT and their corresponding relapses (90
LR and 50 DM). Clinical and pathological features of the
PT are shown in Table 2. The mean interval of LR was
55 months (range, 5–232 months); sites of LR were: breast
(21), chest wall (44), axilla (23) and homolateral clavicular
nodes (two). All samples of LR were surgical specimens.
Forty-six DM were metachronous and four synchronous.
The mean interval of metachronous DM was 73.6 months
(range, 6–216 months). The sites of metachronous DM
were: liver (five), lung (nine), pleura (two), bone (ten), skin
(three), ovary (three), peritoneum (one), stomach (five),
duodenum (three), thyroid (one), cervix (one) and node
(three). The sites of synchronous DM were: colon (one),
bone (one), node (one) and brain (one). Twenty-seven
samples of DM were surgical samples, whereas 23 were
bioptic specimens.
The results regarding ER, PR and HER-2 status in PT
and corresponding metastatic sites are shown in Table 3.E R
and PR status was available for all 140 paired samples,
whereas HER-2 status for 136 paired samples, since four
cases were not evaluable due to unreliable tissue process-
ing. In these cases, the chromosome 17 marker could not be
identified by SISH analysis. We found ten cases with
significant changes between the original report and the
reassessed IHC staining. In five cases, there was a different
ER value, while in the remaining cases differences in PR
were seen, all in the PT.
A discrepancy in ER was present in nine (6.4%) of
paired samples, eight (7.2%) lost and one (3.4%) gained ER
(P=0.04). In four (three loss and one gain) of these nine
paired samples, there was a similar discrepancy in PR,
while in the other five cases with ER loss, PR was negative
in both PTand relapse.
A change in PR status was present in 30 (21.4%) of
paired samples; 25 (27.5%) lost and five (10.2%) gained
PR (P=0.0003). The change rate between PR and ER was
statistically significant (P=0.0004).
Comparison between LR and DM showed a difference
not statistically significant with regards to the rate of
Table 2 Clinical and pathologic features of 140 primary breast
tumours
Primary tumours
Age (years)
Mean 61.7
Range 34–93
Size (cm)
Mean 2.6
Range 0.5–9.5
Histologic type
Ductal 101
Lobular 32
Others 7
Grading
G1 24
G2 63
G3 53
ER status
Positive 111
Negative 29
PR status
Positive 91
Negative 49
HER-2 status
Positive 18
Negative 118
Non-informative 4
Therapy
None 43
CT 25
HT 24
CTand HT 36
Not available 12
ER estrogen receptor, PR progesterone receptor, CTchemotherapy, HT
hormone therapy
4 Virchows Arch (2011) 459:1–10change in ER (P=0.72), while it showed a trend towards a
statistical significance for change in PR, more frequent in
DM than in LR (P=0.03). This trend was maintained even
in the group of untreated patients (P=0.02).
HER-2 change was present in 5 of 136 paired samples
(3.7%) using IHC and in only one paired samples after SISH
(0.7%). In four of these IHC–HER-2-shifted paired samples,
there was discordance between IHC and SISH; one sample
was IHCpositiveand SISH negative,whereas three wereIHC
negative and SISH positive. Analysis of the our case with
HER-2 shift showed a PT negative to IHC and not amplified
to SISH, while the axillary recurrence, developed 96 months
after mastectomy and axillary lymph node dissection, showed
IHCpositivityandSISHamplification.Thecomparisonofthe
two tumours demonstrated a shift from primary ductal type
carcinoma (E-cadherin positivity) to lobular type carcinoma
(E-cadherin negativity) (Fig. 1). In no other case, there was a
change in histologic type and E-cadherin expression between
PTand corresponding relapse.
The relationship between hormone receptor status and
therapy is shown in Table 4. Thirty-six patients were treated
with chemotherapy associated with hormone therapy, 25
were treated with chemotherapy only and 24 were treated
with hormone therapy only. Forty-three patients received no
adjuvant therapy. In this latter group, we included the four
patients with synchronous DM, considering that hormone
receptor status could not be affected by therapy. Only five
patientsweretreatedwithtrastuzumab(twowithLRandthree
with DM). There was no clinical information in 12 patients.
There were not statistically significant differences in ER
changeamongthefourgroupsofpatients,whereastherewasa
statistically significant PR loss in patients treated with
chemotherapy and hormone therapy (P=0.0005). There were
no significant associations between histological type (ductal
vs lobular), grading (G1–G2 vs G3), Ki-67(low < median
value, 14% vs high ≥ median value, 14) and hormone
receptors shift (data not shown).
Clinical results
The analysis of MFS in the subset of patients with ER
positive PT and LR, but with different PR status was
possible in 56 patients: 20 patients with ER negative PT,
five patients with ER negative LR and nine patients with
DM prior or synchronous to LR were excluded. Out of 56
patients evaluated, there was only one patient with PR
negative PT and positive LR. This single patient was
excluded from analysis. Therefore, we overall analysed
MFS in 55 patients.
Kaplan–Meier MFS curves (Fig. 2) showed a significant
difference in MFS among groups of patients with ER
positive local recurrence but different PR status: primary
tumour and local recurrence both PR positive (group A, 40
patients); primary tumour and local recurrence both PR
negative (group B, seven patients) and primary tumour PR
positive and local recurrence PR negative (group C, eight
patients). Group C patients had significantly worse MFS
(median 24.1 months) compared with group A patients
(median 111.8 months) (log-rank=0.005). Multivariate
analysis showed that PR status in LR was independently
associated with MFS and that PR loss in LR (group C) was
also strongly associated with poor outcome: hazard ratio,
8.9 (95% CI, 2.3–34.5) (P=0.002).
Discussion
The development of target therapy has changed the
prognosis of patients both in adjuvant and metastatic setting
[34–38]. Although therapy targets metastases, the hormone
receptors and HER-2 status are almost always evaluated on
PT [1–3, 5–7]. Thus, it is crucial to determine whether
there is concordant biomarkers expression between PT and
corresponding metastasis, since the data available from
literature show very discordant results about this issue
(Table 1)[ 1–30]. In almost all previous reports, the adopted
threshold of positivity for hormone receptors is ≥10% of
neoplastic cells [3–5, 10, 14–16, 18, 28, 30], while for
HER-2 is >10% of neoplastic cells with intense continuous
membrane staining for IHC [1, 3, 7, 13, 22, 25] or ratio >2
for in situ hybridisation [1–3, 13, 21, 26]. The recent
ASCO/CAP guidelines considered receptor positive for a
tumour with a minimum of 1% of positive tumour cells [32]
and HER-2 positive for a tumour with an intense
Table 3 Change of ER, PR and HER-2 in different metastatic sites
ER PR HER-2
Change Pos–neg Neg–pos Change Pos–neg Neg–pos Change Pos–neg Neg–pos
LR 5/90 (5.5%) 5/70 (7.1%) 0/20 14/90 (15.5%) 11/58 (18.9%) 3/32 (9.3%) 1/88 (1.1%) 0/11 1/77 (1.3%)
DM 4/50 (8%) 3/41 (7.3%) 1/9 (11.1%) 16/50 (32%) 14/33 (42.4%) 2/17 (11.8%) 0/48 0/7 0/41
Total 9/140 (6.4%) 8/111 (7.2%) 1/29 (3.4%) 30/140 (21.4%) 25/91 (27.5%) 5/49 (10.2%) 1/136 (0.7%) 0/18 1/118 (0.8%)
LR local recurrences, DM distant metastases, ER estrogen receptor, PR progesterone receptor
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Fig. 1 Different morphology
(H&E) between ductal like
primary tumour (a) and lobular
like local recurrence (b). Immu-
nohistochemistry showed
different staining for E-cadherin
and HER-2 between the
primary tumour (c, e) and the
recurrence (d, f)
Table 4 Correlation between changes in ER, PR and therapy
ER PR
Change Pos–neg Neg–pos Change Pos–neg Neg–pos
CT 0/25 0/10 0/15 2/25 (8%) 0/8 2/17 (11.7%)
HT 1/24 (4.1%) 1/24 (4.1%) 0/0 6/24 (25%) 4/18 (22.2%) 2/6 (33%)
CTand HT 2/36 (5.5%) 2/34 (5.9%) 0/2 12/36 (33.3%) 12/29 (41.4%) 0/7
None 6/43 (13.9%) 5/31 (16.1%) 1/12 (8.3%) 6/43 (13.9%) 5/26 (19.2%) 1/17 (5.9%)
ER estrogen receptor, PR progesterone receptor, CTchemotherapy, HT hormone therapy
6 Virchows Arch (2011) 459:1–10continuous staining in >30% of neoplastic cells in IHC and/
or a ratio >2.2 in situ hybridisation [33]. In this work, we
have adopted the positivity threshold proposed by the
ASCO/CAP guidelines. We reassessed ER, PR and HER-2
status in PT and corresponding metastasis in 140 paired
samples including 90 LR and 50 DM.
We found a significant change for hormone receptors
between the original report and the reassessed IHC staining
in 3.6% of samples, all in the PT. In these tumour samples,
the original report was done before 2000. Amir et al.
reported a change in 5.8%, 11.5% and 8.7% after
reassessment for ER, PR and HER-2, respectively [9]. This
discrepancy might be due to differences in analytic factors
such as use of manual or automated methods, tests reagents
and type of antigen retrieval.
T h er a t eo fc h a n g ei nE Rs t a i n i n gw a s6 . 1 % .O v e r a l l ,
there was a trend towards a statistical significance for ER
loss (P=0.04). ER change was not affected by therapy. In
agreement with Shimizu et al. [24], in the majority of our
cases with ER change, there was a corresponding change
in PR status. This is likely due to fact that PR is regulated
by ER [39].
A change in PR status was seen in 21.4% of cases,
significantly more frequently than ER change (P<0.0001).
These data are in agreement with the majority of previous
publications [4, 8, 9, 11, 17–20, 23, 24, 27]. Overall, a PR
positive PT with a negative relapse was the most frequent
event (P=0.0003).
Overall, we had six cases in which the PT was negative
for hormone receptors (one ER and five PR), but the
corresponding relapse was positive. This event has been
reported by other authors [4, 9, 11, 15, 17, 19, 20, 23, 27].
False negative assessment in PT cannot be excluded;
however, our cases showed hormone receptors positive
control in normal breast tissue associated with the PT,
ruling out the possibility that technical factors, including
poor fixation, influenced the different receptors status.
While the loss of hormone receptors, during metastasis
process, might be related with clonal selection or tumour
dedifferentiation, these mechanisms could not explain
hormone receptors gain. Molecular analyses showed the
presence of different clones of cells having different genetic
profile in the same tumour; metastasis might be established
by one of these clones. The parallel progression model
posits parallel, independent evolution of metastasis arising
from early disseminated tumour cells clone rather than a
linear progression of primary tumour to metastasis [40].
HER-2 change was present in 3.7% of paired samples
using IHC and in only 0.7% after SISH analysis. In four
o ft h e s ef i v eI H C –HER-2-shifted paired samples, there
was discordance between IHC and SISH. In discordant
cases, the reassessment of HER-2 status on PT and
relapse with both techniques is warranted. The analysis
of the case with HER-2 shift showed an HER-2 negative
PT to IHC and SISH and a HER-2 positive axillary
recurrence to IHC and SISH. The comparison of the two
tumours demonstrated a shift from primary ductal type
carcinoma (E-cadherin positivity) to lobular type carci-
noma (E-cadherin negativity) (Fig. 2). Although Wu et al.
reported a similar case of E-cadherin positive primary
ductal carcinoma with corresponding multiple metastases
characterized by lobular morphology and E-cadherin loss
C  B A
Fig. 2 Kaplan–Meier estimate
of metastasis free survival
according to PT/LR receptor
status. Groups (A, B,C )
are defined in Clinical results
Virchows Arch (2011) 459:1–10 7expression [41], a second tumour arising from residual
mammary parenchyma rather than a real recurrence can be
supposed. Indeed, there are no reliable morphologic or
clinical criteria to distinguish LR from secondary tumour.
Clinically, controlateral cancer is generally considered to
represent independent tumour, in ipsilateral disease,
tumour having a longer mean time to recurrence or
occurring in different quadrant from the initial tumour is
also regarded as new primary tumour. Finally, concerning
pathological features, the presence of in situ carcinoma,
different histological type or better differentiation of
second tumour may help in identifying independent
tumours [42]. Research using genomic analyses may
replace these criteria [43].
Changes in PR status were more frequent in DM than
LR (P=0.003) and this trend was maintained in patients not
undergoing any therapy (P=0.002). Most of previous
papers, investigating the difference in hormone receptor
status between DM and LR, have shown a similar rate of
discordance between DM and LR [17, 20, 23, 27], while
Idirisinghe et al. demonstrated a higher rate of discordance
for both ER and PR in DM [4]. A higher rate of HER-2
shift in DM in comparison to LR has been reported by
several authors [2, 4, 21, 22, 26]. Since LR was made up
exclusively of surgical specimens and nearly half of DM of
bioptic specimens, one possible reason for this difference
might be related to the size of the samples analysed. The
discordance rate of hormone receptors and HER-2 between
core biopsy and corresponding surgical specimen in breast
cancer varies from 1% [44] to 18.7% [45] for hormone
receptors and from 1.2% [46] to 13.5% [44] for HER-2.
However, in our cases of DM, there was no statistically
significant difference in ER and PR change between
bioptic (n=23) and surgical (n=27) specimens (P=0.61
and P=0.55, respectively). Thus, it is likely that the
greater degree of biomarkers change in DM compared
with either LR likely reflects the complex biologic process
to establish growth in a new site. The basic steps of
metastasis include the progression of the PT towards
dispersion of cancer cells through the blood vessels.
Circulating cancer cells could infiltrate distant organs
and, in the new microenvironment, might proceed towards
overt metastasis [47].
Regarding therapeutic implications, since there were
no ER negative/PR positive tumour samples, there was a
theoretical change in clinical management in 7.3% of
patients corresponding to nine cases with ER change and
to case with HER-2 change. Amir et al. [9], Locatelli et
al. [19] and Thompson et al. [27] reported a therapeutic
change of management in 15.1%, 12.1% and 17.5%,
respectively. Simmons et al. [5] demonstrated a significant
change in patient management in 6 of 29 cases (20%).
However, in that prospective study, the diagnosis of
suspicious “metastatic” biopsy was a benign lesion in
three cases and lymphoma in one case. Consequently, in
only 2 of 25 cases (8%) was there a change in management
due to a genuine change in biomarker status.
Concerning the relation between hormone receptor
change and therapy, we showed that ER change was not
affected by therapy (P=0.7), whereas a significant change
was observed only for PR loss in patients who underwent
chemotherapy and hormone therapy (P<0.0005). Li et al.
demonstrated a lack of influence of hormone therapy and
chemotherapy on ER and PR status [17], while Idirisinghe
et al. showed a correlation between ER and PR loss and
hormone therapy [4]. Sequential breast cancer biopsies
have shown that ER levels are reduced slightly with
intervening endocrine therapy, while PR levels decrease
more dramatically with up to half of tumours completely
losing PR expression when resistance develops [48].
Few studies have shown a shorter survival among
women with ER negative metastatic and locally recurrent
tumours, regardless of the primary tumour ER status [4, 20],
while whether and how the loss of PR affects the clinical
course of ER positive/PR negative metastatic tumours
remains to be clarified [48]. The study of Brankovic-Magic
et al., based on reports review of 23 breast cancer and
corresponding metastases, suggests that PR loss in metastasis
may be an important marker in predicting response failure to
endocrine therapy in metastatic disease [49].
In our study, the analysis of patients with ER positive
P Ta n dL Rs h o w e dt h a tt h eM F Sw a ss i g n i f i c a n t l yw o r s e
in patients with a PR positive PTand negative LR than in
those with both PR positive PT and LR (log-rank=0.01)
(Fig. 2). Noteworthy, all the eight patients with ER
positive PT and LR who lost PR in LR had received
therapy after LR diagnosis: six had hormone therapy, one
had chemotherapy and one hormone therapy associated to
chemotherapy. The very short median MFS time (24 months)
observed in this group of patients seems to indicate that
hormone therapy, received by seven out of eight PR-shifted
patients, may be not enough to treat this disease. A more
aggressive approach by combining extensive local therapy
with chemotherapy and hormone therapy is probably
required. Nevertheless, our data clearly indicate that PR-
shifted patients have a poor prognosis and should be
accurately followed-up after their LR.
In summary, in the present study, a change between PT
and corresponding metastasis was frequent for PR and less
frequent for ER, whereas it was very rare for HER-2. In
cases with HER-2 shift, reassessment of HER-2 status on
PT and corresponding relapse with both techniques (IHC
and in situ hybridisation) is warranted. Changes in
biomarkers may occur sporadically, preferably in DM
compared to LR, although the loss of PR appears to be
affected by chemotherapy associated to hormone therapy. In
8 Virchows Arch (2011) 459:1–10patients with ER positive PT and LR, PR loss in LR
correlates with a more aggressive behaviour of the tumour.
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